Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) has granted 12,900 restricted stock units (RSUs) to four new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% on the one-year anniversary of the recipient's vesting commencement date, with the remaining 75% vesting in twelve equal quarterly installments thereafter. These grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in accordance with NASDAQ Listing Rule 5635(c)(4). The vesting is contingent upon continued employment with Esperion.
Esperion (ESPR) reported strong Q3 2024 financial results with total revenue increasing 52% year-over-year to $51.6 million. U.S. net product revenue grew 53% to $31.1 million, driven by retail prescription growth. Total retail prescription equivalents increased 12% and new to brand prescriptions grew 18% from Q2. The company expanded product labels, scaled up commercial team, and strengthened balance sheet by monetizing European royalties. Over 165 million lives now have updated utilization management criteria aligned to new labels across Commercial, Medicare and Medicaid payers. Cash and cash equivalents totaled $144.7 million as of September 30, 2024.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Jefferies London Healthcare Conference scheduled for Tuesday, November 19, 2024, at 11:30 a.m. ET. The event will be webcasted live on Esperion's investor and media section website, with replay access available approximately two hours after the call and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels as effectively as possible, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (NASDAQ: ESPR) announced the acceptance of four presentations at the 2024 American Heart Association (AHA) Scientific Sessions in Chicago. The presentations include one featured presentation in the Late Breaker/Featured Science track focusing on bempedoic acid and limb outcomes in statin-intolerant patients with peripheral artery disease from the CLEAR Outcomes Trial. Additionally, three poster presentations will cover liver steatosis and cardiovascular events, statin intolerance effects on patient management, and real-world effectiveness of bempedoic acid plus ezetimibe therapy.
Esperion (NASDAQ: ESPR) has announced it will report its third quarter 2024 financial results on Thursday, November 7, 2024, before market opens. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates. A live audio webcast will be accessible through Esperion's website, with the replay available for approximately 90 days after the call. The company focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol treatment.
Esperion announced final 2-year follow-up data from the German cohort of the MILOS study, evaluating real-world use of bempedoic acid in patients with primary hypercholesterolemia or mixed dyslipidemia. The study showed:
- A 30.3% average relative reduction in LDL-C levels from pre-treatment to 2 years
- An increase in patients reaching LDL-C goals from 4.9% to 35.3% at 2-year follow-up
- Over 80% of patients received bempedoic acid with other lipid-lowering therapies
- Safety profile consistent with the CLEAR clinical trial program
The data demonstrates the effectiveness of bempedoic acid in real-world settings, supporting its role in helping patients achieve LDL-C goals and potentially reducing cardiovascular event risks.
Esperion (NASDAQ: ESPR) announced on September 25, 2024, that it granted 3,500 restricted stock units (RSUs) to a new employee on September 23, 2024, under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for granting equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSUs will vest as follows: 25% on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET. The event will be webcasted live and accessible through Esperion's investor and media website section. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a company focused on discovering, developing, and commercializing innovative medicines for patients with or at risk of cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next steps in LDL-cholesterol reduction.
Esperion announced expanded coverage for NEXLETOL® and NEXLIZET®, their FDA-approved non-statin medications for lowering LDL cholesterol and reducing cardiovascular risk. The drugs now have access to over 92% of commercially insured lives and 65% of Medicare lives, totaling more than 170 million covered individuals. This increased coverage follows the FDA's approval of expanded indications for both primary and secondary prevention patients.
The improved formulary status and streamlined prior authorization processes make it easier for healthcare providers to prescribe these medications. NEXLETOL and NEXLIZET are unique in being the only non-statins FDA-approved for both LDL-C reduction and cardiovascular risk reduction in patients unable to take recommended statin therapy.
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. The event will be webcasted live and accessible through the investor and media section of Esperion's website. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a pharmaceutical company focused on developing innovative medicines for cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next-step solutions in reducing LDL-cholesterol levels. The company emphasizes the importance of lowering cholesterol levels as much as possible, as quickly as possible.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
